Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 155.29 Million EUR | -6.84% |
| 2022 | 166.69 Million USD | 3.16% |
| 2021 | 161.59 Million EUR | -0.38% |
| 2020 | 162.21 Million EUR | 179.03% |
| 2019 | 58.13 Million EUR | -30.31% |
| 2018 | 83.42 Million EUR | -14.47% |
| 2017 | 97.53 Million EUR | 37.61% |
| 2016 | 70.87 Million EUR | 308.63% |
| 2015 | 17.34 Million EUR | 796.55% |
| 2014 | 1.93 Million EUR | -28.99% |
| 2013 | 2.72 Million EUR | -27.87% |
| 2012 | 3.77 Million EUR | -15.11% |
| 2011 | 4.44 Million EUR | 0.0% |
| 2010 | - EUR | -100.0% |
| 2009 | 41.96 Million EUR | -20.18% |
| 2008 | 52.57 Million EUR | 129.4% |
| 2007 | 22.91 Million EUR | 999.75% |
| 2006 | 2.08 Million EUR | 830.96% |
| 2005 | 223.85 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 122.02 Million EUR | -20.39% |
| 2024 Q3 | 95.41 Million USD | -4.53% |
| 2024 Q1 | 167.2 Million USD | -2.53% |
| 2023 FY | 155.29 Million EUR | -6.84% |
| 2023 Q4 | 171.54 Million USD | 4.61% |
| 2023 Q3 | 163.98 Million USD | -3.61% |
| 2023 Q2 | 170.13 Million USD | -0.16% |
| 2023 Q1 | 170.39 Million USD | 2.22% |
| 2022 Q4 | 166.69 Million USD | 19.77% |
| 2022 Q2 | 149 Million USD | -5.57% |
| 2022 Q3 | 139.18 Million USD | -6.59% |
| 2022 FY | 166.69 Million USD | 3.16% |
| 2022 Q1 | 157.78 Million USD | 10.56% |
| 2021 Q2 | 170.46 Million EUR | 10.97% |
| 2021 FY | 161.59 Million EUR | -0.38% |
| 2021 Q3 | 164.78 Million EUR | -3.33% |
| 2021 Q4 | 142.72 Million EUR | -13.39% |
| 2021 Q1 | 153.6 Million EUR | -5.31% |
| 2020 FY | 162.21 Million EUR | 179.03% |
| 2020 Q1 | 140.36 Million EUR | 141.44% |
| 2020 Q2 | 144.97 Million EUR | 3.29% |
| 2020 Q3 | 152.67 Million EUR | 5.31% |
| 2020 Q4 | 162.21 Million EUR | 6.25% |
| 2019 Q4 | 58.13 Million EUR | -12.24% |
| 2019 Q3 | 66.24 Million EUR | -11.21% |
| 2019 FY | 58.13 Million EUR | -30.31% |
| 2019 Q2 | 74.6 Million EUR | -7.04% |
| 2019 Q1 | 80.25 Million EUR | -3.8% |
| 2018 Q2 | 96.59 Million EUR | -0.31% |
| 2018 Q3 | 90.4 Million EUR | -6.4% |
| 2018 FY | 83.42 Million EUR | -14.47% |
| 2018 Q4 | 83.42 Million EUR | -7.73% |
| 2018 Q1 | 96.89 Million EUR | -0.65% |
| 2017 Q1 | 70.09 Million EUR | -1.11% |
| 2017 FY | 97.53 Million EUR | 37.61% |
| 2017 Q4 | 97.53 Million EUR | -6.08% |
| 2017 Q3 | 103.84 Million EUR | 0.32% |
| 2017 Q2 | 103.51 Million EUR | 47.69% |
| 2016 FY | 70.87 Million EUR | 308.63% |
| 2016 Q1 | 17.46 Million EUR | 0.7% |
| 2016 Q4 | 70.87 Million EUR | 313.79% |
| 2016 Q2 | 17.69 Million EUR | 1.33% |
| 2016 Q3 | 17.12 Million EUR | -3.22% |
| 2015 Q3 | 18.37 Million EUR | 1381.41% |
| 2015 Q1 | 1.31 Million EUR | -31.88% |
| 2015 FY | 17.34 Million EUR | 796.55% |
| 2015 Q2 | 1.24 Million EUR | -5.87% |
| 2015 Q4 | 17.34 Million EUR | -5.61% |
| 2014 Q3 | 1.95 Million EUR | -13.93% |
| 2014 FY | 1.93 Million EUR | -28.99% |
| 2014 Q2 | 2.26 Million EUR | 1.46% |
| 2014 Q4 | 1.93 Million EUR | -0.87% |
| 2014 Q1 | 2.23 Million EUR | -17.97% |
| 2013 Q2 | 11.74 Million EUR | -25.67% |
| 2013 FY | 2.72 Million EUR | -27.87% |
| 2013 Q4 | 2.72 Million EUR | -58.17% |
| 2013 Q3 | 6.51 Million EUR | -44.54% |
| 2013 Q1 | 15.8 Million EUR | 318.35% |
| 2012 Q4 | 3.77 Million EUR | -4.06% |
| 2012 Q1 | 8.23 Million EUR | 85.07% |
| 2012 FY | 3.77 Million EUR | -15.11% |
| 2012 Q3 | 3.93 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 Q1 | - EUR | -100.0% |
| 2011 Q3 | - EUR | 0.0% |
| 2011 Q4 | 4.44 Million EUR | 0.0% |
| 2011 FY | 4.44 Million EUR | 0.0% |
| 2010 Q3 | 15.14 Million EUR | -64.01% |
| 2010 FY | - EUR | -100.0% |
| 2010 Q4 | 102.4 Thousand EUR | -99.32% |
| 2010 Q2 | 42.09 Million EUR | -13.55% |
| 2010 Q1 | 48.68 Million EUR | 16.03% |
| 2009 FY | 41.96 Million EUR | -20.18% |
| 2009 Q4 | 41.96 Million EUR | 0.0% |
| 2008 FY | 52.57 Million EUR | 129.4% |
| 2007 FY | 22.91 Million EUR | 999.75% |
| 2006 FY | 2.08 Million EUR | 830.96% |
| 2005 FY | 223.85 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | 3.39 Million EUR | -4480.93% |
| ABIVAX Société Anonyme | 55.46 Million EUR | -179.99% |
| Adocia SA | 13.08 Million EUR | -1086.534% |
| Aelis Farma SA | 4.03 Million EUR | -3745.803% |
| Biophytis S.A. | 8.27 Million EUR | -1777.794% |
| Advicenne S.A. | 17.42 Million EUR | -791.211% |
| genOway Société anonyme | 7.23 Million EUR | -2046.894% |
| IntegraGen SA | 1.12 Million EUR | -13707.122% |
| Medesis Pharma S.A. | 1.2 Million EUR | -12841.128% |
| Neovacs S.A. | 650 Thousand EUR | -23791.312% |
| NFL Biosciences SA | 62.17 Thousand EUR | -249672.463% |
| Plant Advanced Technologies SA | 4.35 Million EUR | -3464.632% |
| Quantum Genomics Société Anonyme | 2.71 Million EUR | -5615.964% |
| Sensorion SA | 2.86 Million EUR | -5313.212% |
| Theranexus Société Anonyme | 3.64 Million EUR | -4162.768% |
| TME Pharma N.V. | 1.16 Million EUR | -13218.485% |
| Valbiotis SA | 6.87 Million EUR | -2157.83% |
| TheraVet SA | 1.15 Million EUR | -13288.908% |
| Valerio Therapeutics Société anonyme | 8.99 Million EUR | -1625.867% |
| argenx SE | 18.1 Million EUR | -757.725% |
| BioSenic S.A. | 28.16 Million EUR | -451.449% |
| Celyad Oncology SA | 902 Thousand EUR | -17116.578% |
| DBV Technologies S.A. | 13.01 Million USD | -1092.859% |
| Galapagos NV | 9.59 Million EUR | -1518.315% |
| Genfit S.A. | 70.17 Million EUR | -121.285% |
| GeNeuro SA | 7.73 Million EUR | -1906.947% |
| Hyloris Pharmaceuticals SA | 5.29 Million EUR | -2833.387% |
| Innate Pharma S.A. | 39.89 Million EUR | -289.275% |
| Inventiva S.A. | 37.4 Million EUR | -315.146% |
| MaaT Pharma SA | 14.07 Million EUR | -1003.329% |
| MedinCell S.A. | 58.96 Million EUR | -163.383% |
| Nanobiotix S.A. | 50.56 Million EUR | -207.117% |
| Onward Medical N.V. | 16.87 Million EUR | -820.312% |
| Oryzon Genomics S.A. | 13.68 Million EUR | -1034.586% |
| OSE Immunotherapeutics SA | 45.8 Million EUR | -239.061% |
| Oxurion NV | 12.33 Million EUR | -1159.069% |
| Poxel S.A. | 46.9 Million EUR | -231.116% |
| GenSight Biologics S.A. | 18.42 Million EUR | -742.704% |
| Transgene SA | 1.25 Million EUR | -12254.298% |
| Financière de Tubize SA | 79.2 Million EUR | -96.078% |
| UCB SA | 3.03 Billion EUR | 94.888% |
| Valneva SE | 208.81 Million EUR | 25.631% |
| Vivoryon Therapeutics N.V. | 38 Thousand EUR | -408567.187% |